- Real-world evidence dataset demonstrates relationship between higher urinary oxalate levels and increased incidence of chronic kidney disease - - Additional clinical data presented on SYNB8802 in a healthy volunteer model of diet-induced hyperoxaluria - - Phase 1b study of SYNB8802 in enteric...

CAMBRIDGE, Mass. , Oct. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in Nature of preclinical research with live biotherapeutic products designed using the...

CAMBRIDGE, Mass. , Sept. 27, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms....

CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering...

CAMBRIDGE, Mass. , Sept. 22, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock....

-- SYNB1618 demonstrated proof of concept with meaningful reduction of plasma phenylalanine (Phe) levels in an interim analysis of the Phase 2 SynPheny-1 Study -- -- SYNB1934, an optimized strain of SYNB1618, demonstrated two-fold increase in biomarkers of Phe metabolism compared to SYNB1618 -- --...

CAMBRIDGE, Mass. , Sept. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of...

- Results of patient and caregiver survey highlight unmet need in PKU, burden of disease, and benefits from addition of natural protein to diet - CAMBRIDGE, Mass. , Sept. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of...

- Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - Immunomodulation portfolio expanded via strategic research collaboration in IBD - - Synlogic ends 2Q 2021 with $115.5 million in cash, cash equivalents...

CAMBRIDGE, Mass. , Aug. 5, 2021 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2021 financial results before the market opens on Thursday,...

- Data show dose-responsive, non-saturated increases in gastrointestinal consumption of Phe in humans by SYNB1618 - - SYNB1618 Phase 2 study in patients with PKU ongoing with proof-of-concept readout anticipated in 2H 2021 - - Phase 1 study of SYNB1934, an evolved strain of SYNB1618 in the PKU...

- SYNB1934, an evolved strain of SYNB1618, has the potential to provide increased benefit to patients living with PKU - - SYNB1934 Phase 1 Study to evaluate safety, tolerability, and head-to-head comparison of biomarkers of Phe-consumption between SYNB1934 and SYNB1618 - - SYNB1618 Phase 2 Study in...